Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

National Cooperative Growth Study (NCGS) of Optimal Nutropin AQ and Nutropin Dosing in Pubertal Growth Hormone-Deficient (GHD) Patients

This study has been completed.
Information provided by:
Genentech, Inc. Identifier:
First received: November 24, 2004
Last updated: November 11, 2010
Last verified: November 2010
This study is a multicenter, open-label, observational, postmarketing surveillance study that will collect information on the use of Genentech GH preparations to treat GH-deficient subjects with optimal GH dosing during puberty.

Condition Phase
Dwarfism, Pituitary
Phase 4

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: National Cooperative Growth Study (NCGS) of Optimal Nutropin AQ and Nutropin Dosing in Pubertal Growth Hormone-Deficient (GHD) Subjects

Resource links provided by NLM:

Further study details as provided by Genentech, Inc.:

Study Start Date: February 2003
Study Completion Date: June 2006

Ages Eligible for Study:   12 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Pubertal Growth Hormone Deficiency

Inclusion Criteria:

  • Adolescent boys who are GH deficient and Tanner Stage 2 or greater (testes 3 mL or greater)
  • Adolescent girls who are GH deficient and breast Tanner Stage 2 or greater
  • Current treatment with GH dose of 0.4 to 0.7 mg/kg/wk
  • Ability to keep follow-up appointments throughout the study
  • Willingness to remain on therapy until epiphyseal closure is achieved
  • Prior enrollment in NCGS Core Study 85-036

Exclusion Criteria:

  • Treatment with non-Genentech GH preparation
  • Closed epiphyses
  • Active neoplasia
  • Treatment with insulin for diabetes
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00097513

United States, California
Genentech Central Contact
South San Francisco, California, United States, 94080
Sponsors and Collaborators
Genentech, Inc.
Study Director: Barbara Lippe, M.D. Genentech, Inc.
  More Information

Responsible Party: Disclosures Group, Genentech, Inc. Identifier: NCT00097513     History of Changes
Other Study ID Numbers: 85-036, Substudy 12
Study First Received: November 24, 2004
Last Updated: November 11, 2010

Keywords provided by Genentech, Inc.:
Pubertal Growth Hormone Deficiency

Additional relevant MeSH terms:
Dwarfism, Pituitary
Bone Diseases, Developmental
Bone Diseases
Musculoskeletal Diseases
Genetic Diseases, Inborn
Endocrine System Diseases
Bone Diseases, Endocrine
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs processed this record on May 25, 2017